长春高新：痛风治疗迎来创新突破 有望填补国内痛风急性期治疗空白

Core Insights - Gout is a common and complex disease in China, with a prevalence rate of approximately 1% to 3%, showing an increasing trend annually [1] - Changchun High-tech's subsidiary, Jinsai Pharmaceutical, has developed a novel IL-1β monoclonal antibody, Vuxin Qibai, which is currently in the application stage for market approval [2][3] - The global and Chinese gout medication market is expected to grow significantly, with projections indicating that the number of patients with hyperuricemia and gout in China will reach 240 million by 2030, and the market size could grow to 10.8 billion yuan [3] Company Developments - Vuxin Qibai has shown significant clinical efficacy, with a 57.09 mm reduction in pain intensity scores within 72 hours and a 90% reduction in the risk of new gout attacks within 12 weeks [2] - The drug is the first IL-1β monoclonal antibody in China to enter the market application phase for acute gout treatment, filling a clinical gap in the country [3] - The injection form of Vuxin Qibai for acute gouty arthritis has received market application acceptance in April 2024, with additional formulations also in various stages of clinical trials [3] Market Context - The current treatment landscape for acute gout in China primarily relies on anti-inflammatory drugs and urate-lowering agents, which have significant side effects and risks [1] - The introduction of Vuxin Qibai is timely, as the demand for effective gout treatments is rising alongside the increasing prevalence of the disease [3] - The successful commercialization of Vuxin Qibai could provide substantial clinical value for gout patients and represent a new growth opportunity for Changchun High-tech [3]